The Lynx Group

Gastric Cancer

San Francisco, CA—Phase 3 data from a global clinical trial have demonstrated an improvement in overall survival (OS) when the investigational angiogenesis inhibitor ramucirumab is added to chemotherapy as second-line therapy in patients with advanced gastric cancer.
Read Article

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: